Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis.

OBJECTIVE The objective of our study was to determine the usefulness of the apparent diffusion coefficient (ADC) of liver parenchyma for determining the severity of liver fibrosis. MATERIALS AND METHODS This study investigated 78 patients who underwent diffusion-weighted imaging (DWI) with 1.5-T MRI and pathologic staging of liver fibrosis based on biopsy. DWI was performed with b values of 50 and 400 s/mm(2). ADCs of liver were measured using 2.0- to 3.0-cm(2) regions of interest in the right and left lobes of the liver; the mean ADC value was used for analysis. Pathologic METAVIR scores for liver fibrosis stage were used as a reference standard. RESULTS The mean ADC values for fibrosis pathologically staged using the METAVIR classification system as F0 (n = 11), F1 (n = 16), F2 (n = 10), F3 (n = 14), and F4 (n = 27) were 125.9, 105.0, 104.5, 103.2, and 99.1 x 10(-5) s/mm(2), respectively. The correlation between the ADC values and the degree of liver fibrosis was moderate (Spearman's test, rho = -0.36). There was a significant difference in ADC values between patients with nonfibrotic liver (F0) and those with cirrhotic liver (F4) (p = 0.008). The best cutoff ADC value to distinguish between these groups was 118 x 10(-5) s/mm(2). However, ADC values were not useful for differentiating viral hepatitis patients with F2 fibrosis or higher from those with a lower degree of fibrosis (area under the receiver operating characteristic curve [AUC] = 0.66) or for differentiating low-stage fibrosis in all patients from high-stage fibrosis in all patients (AUC = 0.54). CONCLUSION The ADCs in cirrhotic livers are significantly lower than those in nonfibrotic livers. However, ADC values measured using the current generation of scanners are not reliable enough to replace liver biopsy for staging hepatic fibrosis.

[1]  S. Saab,et al.  Treatment of hepatitis C. , 2005, The American journal of medicine.

[2]  B. V. Van Beers,et al.  Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. , 2003, Radiology.

[3]  C. Gluud,et al.  Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. , 2001, Liver.

[4]  Isamu Ohashi,et al.  Apparent diffusion coefficient measurements with diffusion‐weighted magnetic resonance imaging for evaluation of hepatic fibrosis , 2005, Journal of magnetic resonance imaging : JMRI.

[5]  Richard L Ehman,et al.  MR elastography of the liver: preliminary results. , 2006, Radiology.

[6]  N. Afdhal,et al.  Evaluation of Liver Fibrosis: A Concise Review , 2004, American Journal of Gastroenterology.

[7]  Claude B Sirlin,et al.  Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. , 2006, Radiology.

[8]  Harsh Kandpal,et al.  Respiratory-triggered versus breath-hold diffusion-weighted MRI of liver lesions: comparison of image quality and apparent diffusion coefficient values. , 2009, AJR. American journal of roentgenology.

[9]  Bachir Taouli,et al.  Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. , 2007, AJR. American journal of roentgenology.

[10]  K. Maruyama,et al.  Diffusion-weighted magnetic resonance imaging of human skeletal muscles: gender-, age- and muscle-related differences in apparent diffusion coefficient. , 2009, Magnetic resonance imaging.

[11]  M Takahashi,et al.  Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. , 1997, Radiology.

[12]  E. Wu,et al.  Diffusion tensor imaging of liver fibrosis in an experimental model , 2010, Journal of magnetic resonance imaging : JMRI.

[13]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[14]  B. Taouli,et al.  Diffusion and perfusion imaging of the liver. , 2010, European journal of radiology.

[15]  S. Dharancy Espoirs et déceptions thérapeutiques - La colchicine , 2006 .

[16]  H. Thomas,et al.  Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease. , 2006, World journal of gastroenterology.

[17]  T. Moteki,et al.  Evaluation of hepatic lesions and hepatic parenchyma using diffusion‐weighted echo‐planar MR with three values of gradient b‐factor , 2006, Journal of magnetic resonance imaging : JMRI.

[18]  D. Pariente,et al.  Paediatric chronic liver diseases: how to investigate and follow up? Role of imaging in the diagnosis of fibrosis , 2010, Pediatric Radiology.

[19]  C. Gluud,et al.  Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. , 2000, Liver.

[20]  Wei-dong Zhao,et al.  Magnetic resonance diffusion-weighted imaging in the diagnosis of diffuse liver diseases in rats. , 2005, Chinese medical journal.

[21]  M. Kaplan,et al.  Regression of Hepatic Fibrosis in Hepatitis C with Long-Term Interferon Treatment , 1998, Digestive Diseases and Sciences.

[22]  O. Pappo,et al.  Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. , 2007, International immunology.

[23]  A. Luciani,et al.  Liver Cirrhosis : Intravoxel Incoherent Motion MR Imaging — Pilot Study 1 , 2008 .

[24]  B. V. Van Beers,et al.  Assessment of diffusion‐weighted MR imaging in liver fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[25]  G. Beaudoin,et al.  Diffusion‐weighted MR imaging of the liver of hepatitis C patients , 2003, NMR in biomedicine.

[26]  Panagiotis Samaras,et al.  Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. , 2007, AJR. American journal of roentgenology.

[27]  R. Malekzadeh,et al.  Reversibility of cirrhosis in autoimmune hepatitis. , 2004, The American journal of medicine.

[28]  Louis Wu,et al.  Liver MRI Technique: Pulse Sequences and Contrast Agents. , 2010, Journal of medical imaging and radiation sciences.

[29]  F. Miller,et al.  MR imaging of hepatocellular carcinoma. , 2010, Magnetic resonance imaging clinics of North America.

[30]  M. Sherman,et al.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. , 2000, Archives of pathology & laboratory medicine.

[31]  T. Ichikawa,et al.  Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. , 1998, AJR. American journal of roentgenology.

[32]  H. Schild,et al.  Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences. , 2002, Radiology.

[33]  C. Zuiani,et al.  Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients , 2007, La radiologia medica.

[34]  C. Zuiani,et al.  Relevance of b‐values in evaluating liver fibrosis: A study in healthy and cirrhotic subjects using two single‐shot spin‐echo echo‐planar diffusion‐weighted sequences , 2008, Journal of magnetic resonance imaging : JMRI.

[35]  Pierre-Yves Boëlle,et al.  Diffusion‐weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C , 2007, Hepatology.